Wedbush Reiterates Outperform on Adicet Bio, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll reiterated an Outperform rating on Adicet Bio (NASDAQ:ACET) and maintained a $5 price target.
April 23, 2024 | 4:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Robert Driscoll reiterated an Outperform rating on Adicet Bio and maintained a $5 price target.
The reiteration of an Outperform rating by a reputable analyst like Robert Driscoll, along with maintaining a $5 price target, signals strong confidence in Adicet Bio's potential. This endorsement is likely to positively influence investor sentiment and could lead to a short-term uptick in ACET's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100